Investment analysts at Evercore ISI began coverage on shares of Nektar Therapeutics (NASDAQ:NKTR) in a research report issued on Thursday, Marketbeat.com reports. The brokerage set an “in-line” rating and a $20.00 price target on the biopharmaceutical company’s stock. Evercore ISI’s target price would suggest a potential upside of 2.46% from the stock’s current price.

A number of other equities analysts have also commented on the company. Jefferies Group LLC dropped their price target on Nektar Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Wednesday, May 10th. Aegis reissued a “buy” rating and set a $27.00 price target on shares of Nektar Therapeutics in a research note on Wednesday, May 10th. Roth Capital set a $31.00 price objective on Nektar Therapeutics and gave the company a “buy” rating in a research note on Thursday, May 11th. William Blair reaffirmed an “outperform” rating on shares of Nektar Therapeutics in a research note on Tuesday, July 18th. Finally, BidaskClub raised Nektar Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $26.10.

Shares of Nektar Therapeutics (NASDAQ NKTR) traded down 5.53% during mid-day trading on Thursday, hitting $18.44. The stock had a trading volume of 711,235 shares. The company’s market cap is $2.88 billion. Nektar Therapeutics has a 12 month low of $11.41 and a 12 month high of $24.88. The stock’s 50-day moving average is $20.56 and its 200 day moving average is $18.52.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by $0.04. Nektar Therapeutics had a negative net margin of 157.14% and a negative return on equity of 1,223.34%. The firm had revenue of $34.60 million for the quarter, compared to the consensus estimate of $33.64 million. During the same period in the previous year, the company posted ($0.36) earnings per share. Nektar Therapeutics’s quarterly revenue was up 5.5% on a year-over-year basis. On average, equities research analysts forecast that Nektar Therapeutics will post ($0.95) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Nektar Therapeutics (NKTR) Receives New Coverage from Analysts at Evercore ISI” was published by American Banking News and is owned by of American Banking News. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/08/17/nektar-therapeutics-nktr-now-covered-by-analysts-at-evercore-isi.html.

In other Nektar Therapeutics news, Director Lutz Lingnau sold 30,000 shares of the firm’s stock in a transaction on Friday, July 14th. The stock was sold at an average price of $20.76, for a total transaction of $622,800.00. Following the transaction, the director now directly owns 53,450 shares in the company, valued at approximately $1,109,622. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Ivan P. Gergel sold 8,389 shares of the firm’s stock in a transaction on Tuesday, July 11th. The stock was sold at an average price of $21.04, for a total value of $176,504.56. Following the transaction, the senior vice president now owns 51,961 shares in the company, valued at $1,093,259.44. The disclosure for this sale can be found here. Over the last quarter, insiders sold 138,389 shares of company stock worth $2,908,403. Company insiders own 6.10% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Flinton Capital Management LLC increased its position in Nektar Therapeutics by 11.1% in the first quarter. Flinton Capital Management LLC now owns 4,480 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 448 shares during the last quarter. First Trust Advisors LP increased its position in Nektar Therapeutics by 8.0% in the first quarter. First Trust Advisors LP now owns 2,249,950 shares of the biopharmaceutical company’s stock valued at $52,806,000 after buying an additional 166,521 shares during the last quarter. Great West Life Assurance Co. Can boosted its stake in shares of Nektar Therapeutics by 7.0% in the first quarter. Great West Life Assurance Co. Can now owns 213,944 shares of the biopharmaceutical company’s stock valued at $5,019,000 after buying an additional 13,956 shares during the period. Tocqueville Asset Management L.P. boosted its stake in shares of Nektar Therapeutics by 16.9% in the first quarter. Tocqueville Asset Management L.P. now owns 234,402 shares of the biopharmaceutical company’s stock valued at $5,501,000 after buying an additional 33,850 shares during the period. Finally, Wells Fargo & Company MN boosted its stake in shares of Nektar Therapeutics by 7.4% in the first quarter. Wells Fargo & Company MN now owns 207,320 shares of the biopharmaceutical company’s stock valued at $4,866,000 after buying an additional 14,202 shares during the period. Institutional investors own 93.02% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.